Bisphosphonates for prevention of bone loss in women with early breast cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Tsoi, Daphne ^a   Khan, Aliya ^b   Nowak, Anna K ^c   Verma, Sunil ^a   Ferguson, Thomas ^d   Pritchard, Kathleen ^a   Cheung, Angela M ^e  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; GONADORELIN AGONIST; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EARLY CANCER; HUMAN; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION;

EID: 70049094440     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007914     Document Type: Review

References (32)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-1541 [: (Print)]
2. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al.Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine 2004;350(12):1189-1199 [: (Electronic)] (Pubitemid 38339363)
3. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al.Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology 2007;25(7):829-836 [: (Electronic)] (Pubitemid 350002883)
4. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008;13(2):187-195 [: (Print)]
5. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, et al.Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008;112(5):1001-1010 [: (Print)] (Pubitemid 351304583)
6. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000;27(2):283-286 [: (Print)] (Pubitemid 30458823)
7. Cheung AM. Tomlinson G. Goss PE. Bone loss with exemestane: Is the jury still out?. Journal of Clinical Oncology 23(36):9433-4; author reply 9433-9435, 2005 Dec 20.
8. Chien AJ. Goss PE. Aromatase inhibitors and bone health in women with breast cancer. Journal of Clinical Oncology 2006Nov 20;24(33):5305-5312
9. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al.Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 2007;25(5):486-492 [: (Electronic)] (Pubitemid 350002953)
10. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al.Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. The Lancet Oncology 2007;8(2):119-127 [: (Print)] (Pubitemid 46158372)
11. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al.Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369(9561):559-570 [: (Electronic)] (Pubitemid 46251559)
12. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). Journal of Bone and Mineral Research 2006;21(8):1215-1223 [: (Print)] (Pubitemid 44128334)
13. Fleming ID, American Joint Committee on Cancer, American Cancer Society, American College of Surgeons. Breast. AJCC Cancer Staging Manual. 5th Edition. Philadelphia: Lippincott-Raven, 1997:294. [: 0397584148]
14. Follmann D. A simple multivariate test for one-sided alternatives. Journal of the American Statistical Association June 1996;91(434):854. (Pubitemid 126412847)
15. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al.Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology 2007;25(7):820-828 [: (Electronic)] (Pubitemid 350002882)
16. Goss PE. Qi S. Josse RG. Pritzker KP. Mendes M. Hu H. Waldman SD. Grynpas MD. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004 March;34(3):384-392 (Pubitemid 38314903)
17. Goss PE. Hadji P. Subar M. Abreu P. Thomsen T. Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Research 2007;9(4):R52. (Pubitemid 350187471)
18. Goss PE. Qi S. Cheung AM. Hu H. Mendes M. Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clinical Cancer Research 2004 Sep 1;10(17):5717-5723 (Pubitemid 39180947)
19. Goss PE. Qi S. Hu H. Cheung AM. The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. Breast Cancer Research and Treatment 2007 July;103(3):293-302.. (Pubitemid 46944512)
20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al.Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 2005;97(17):1262-1271 [: (Electronic)] (Pubitemid 41535367)
21. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al.Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis and Rheumatism 1999;42(6):1246-1254 [: (Print)] (Pubitemid 29268962)
22. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. The Journal of Clinical Endocrinology and Metabolism 2002;87(4):1586-1592 [: (Print)] (Pubitemid 34615244)
23. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al.Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-62 [: (Electronic)]
24. Martyn-St James M, Carroll S.High-intensity resistance training and postmenopausalbone loss: ameta-analysis. Osteoporosis International 2006;17(8):1225-1240
25. Meunier PJ, Arlot M, Chavassieux P, Yates AJ. The effects of alendronate on bone turnover and bone quality. International Journal of Clinical Practice. Supplement 1999;101:14-17 [: (Print)] (Pubitemid 29216600)
26. Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, et al.Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study - NCICCTGMA.5. Journal of Clinical Oncology 2005;23(25):6002-6008 [: (Print)] (Pubitemid 46300217)
27. Pavlakis N, Schmidt RL, Stockler MR. Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003474]
28. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al.Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Journal of Clinical Oncology 2006;24(22):3629-3635 [: (Electronic)] (Pubitemid 46630537)
29. Riggs BL. The mechanisms of estrogen regulation of bone resorption. The Journal of Clinical Investigation 2000;106(10):1203-1204 [: (Print)]
30. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of Clinical Oncology 2001;19(14):3306-3311 [: (Print)] (Pubitemid 32642182)
31. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. The Journal of Clinical Endocrinology and Metabolism 2000;85(1):231-236 [: (Print)]
32. World Health Organization. Prevention and management of osteoporosis. World Health Organization Technical Report Series 2003; Vol.921:1-164, back cover. [: (Print)]